Trial Profile
Pharmacokinetics and safety of aclidinium bromide, a novel long-acting, inhaled anticholinergic, in healthy subjects.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 05 Nov 2010
Price :
$35
*
At a glance
- Drugs Aclidinium bromide (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Almirall S.A.
- 05 Nov 2010 New trial record.